Cellyan Biotechnology Co., Ltd filed a proxy statement for an extraordinary general meeting scheduled for September 21, 2026. The company proposes a one-for-twenty reverse stock split of its Class A and Class B ordinary shares to increase the per-share trading price and regain compliance with Nasdaq's minimum bid price requirement. The consolidation would change the par value from US$0.001 to US$0.02 and reduce authorized share capital from 1,000,000,000 to 50,000,000 shares. Fractional shares will be rounded up to one whole share. The effective date is contingent on Nasdaq confirmation. Cellyan Biotechnology Co., Ltd operates in the biotechnology industry.

Cellyan Biotechnology received a notification from Nasdaq on July 14, 2026, granting an additional 180-day grace period to regain compliance with the minimum $1.00 closing bid price requirement. The company must maintain a closing bid price of at least $1.00 per Class A ordinary share for ten consecutive business days on or before January 11, 2027. This extension follows a previous deficiency notice issued on January 12, 2026. The company may consider a reverse share split to restore compliance. Cellyan Biotechnology provides over the counter pharmaceutical cross-border e-commerce supply chain services.